目的 探讨CT引导下经皮穿刺微波凝固治疗(PMCT )联合131 I肿瘤细胞核人鼠嵌合单克隆抗体注射液(131I-chTNT)治疗局部中晚期老年非小细胞肺癌(NSCLC)的临床疗效及安全性.方法 78例Ⅲb~ Ⅳ期不可手术切除的老年NSCLC患者分成2组 :对照组(37例)行化疗联合放疗 ;观察组(41例)行微波凝固联合131 I-chTNT放射免疫治疗.对比分析2组患者的临床疗效、生存质量、不良反应发生率及生存率.结果 对照组和观察组患者的治疗有效率分别为46% 和68% ,差异有统计学意义( P<0. 05 );对照组 K PS评分改善率为54% ,观察组为78% ,差异有统计学意义( P<0. 05 );对照组与观察组1年生存率分别为49% 和59% ,中位生存时间分别为340 d和389 d ,差异无统计学意义( P>0. 05 ).观察组的不良反应发生率明显比对照组低 ,差异有统计学意义(P<0.05).结论 微波凝固联合131 I-chTNT放射免疫综合治疗不可手术切除的中晚期老年 NSCLC短期疗效优于同期放化疗方案 ,不良反应低 ,患者耐受良好 ,是一种安全、有效的治疗方法.%Objective To observe the clinical efficacy of microwave ablation combined with 131 I-chTNT ra-dioimmunotherapy to treat non-small cell lung cancer (NSCLC) .Methods Seventy-eight patients who were path-ologically confirmed with NSCLC were divided into two groups ,control group (37 cases) with docetaxel combined with cisplatin in the treatment ;observation group (41 cases) with CT-guided percutaneous microwave ablation combined with 131 I-chTNT radioimmunotherapy .Results The effective rate of observation group was 68% ,signif-icantly higher than 46% of the control group .The difference was statistically significant between two groups (P<0 .05) ;after treatment ,the observation group improved more obviously ,and the difference was statistically sig-nificant between two groups (P<0 .05);the side effects occurred in the observation group were significantly less than those of the control group ,and the difference was statistically significant between two groups (P<0 .05) . Conclusion The treatment of NSCLC by microwave ablation combined with 131 I-chTNT radioimmunotherapy has satisfactory clinical efficacy and reliable security .
展开▼
